You are here: Home » Companies » News
AquaExchange raises $3 mn from Endiya Partners, Accion Venture Lab
JB Chem gets board approval to acquire Dr Reddy's 4 brands for Rs 98 cr
Business Standard

Dr Reddy's settles patent litigation with Indivior, Aquestive Therapeutics

Dr Reddy's Laboratories on Thursday said it has settled patent litigation with Indivior Inc and Aquestive Therapeutics on a medication used to treat opioid dependence or addiction

Topics
Dr Reddys | litigation | Indivior vs Dr Reddys

Press Trust of India  |  New Delhi 



Dr Reddy's
Dr Reddy's

Dr Reddy's Laboratories on Thursday said it has settled patent with Indivior Inc and Aquestive Therapeutics on a medication used to treat opioid dependence or addiction.

On June 28, 2022, a US Court dismissed all claims and counterclaims pending in the case with prejudice, pursuant to a joint stipulation of dismissal filed by the parties, the Hyderabad-based drug major said in a statement.

The stipulation of dismissal was filed pursuant to a settlement agreement that the company entered into with Indivior and Aquestive, it added.

"The settlement and dismissal resolve all claims between the parties, including Indivior's and Aquestive's claims for patent infringement as well as the company's antitrust counterclaim against Indivior," Dr Reddy's said.

On June 24, Dr Reddy's announced that it has entered into a settlement agreement with Indivior Inc and Aquestive Therapeutics as a result of which it will receive payments totalling USD 72 million by March 31, 2024.

The said agreement resolves all claims between the parties relating to the company's generic buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages, it had said.

Buprenorphine and naloxone sublingual film medication is used to treat opioid dependence or addiction.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Thu, June 30 2022. 11:43 IST

RECOMMENDED FOR YOU

.